RNAC

Cartesian Therapeutics, Inc. (RNAC) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Cartesian Therapeutics is a late clinical-stage biotechnology company developing mRNA-based cell therapies for autoimmune diseases. The company's lead candidate, Descartes-08, is in Phase 3 development for myasthenia gravis (MG) and Phase 2 for myositis. The company has no approved products and relies on equity financings, grants, and collaboration agreements for funding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 93% to $78,000, driven by a drop in grant revenue from the National Institute of Neurological Disorders and Stroke (NINDS) and the absence of collaboration revenue recognized in the prior year.
• Increased Net Loss: Net loss more than doubled to $39.2 million. This was primarily due to a $13.8 million non-cash loss from the change in fair value of the CVR liability and a 33% increase in R&D expenses.
• R&D Expense Growth: R&D expenses rose to $19.5 million, largely due to costs associated with the Phase 3 AURORA trial for Descartes-08 in MG. This was partially offset by reduced spending on early-stage programs following the decision to discontinue development for systemic lupus erythematosus.
• Financing Activity: The company raised approximately $14.6 million in net proceeds through an "at-the-market" (ATM) equity offering, selling 2.27 million shares.
• Cash Burn: Net cash used in operating activities was $22.1 million, a slight decrease from $23.1 million in the prior year, though the cash balance declined by $6.5 million overall due to operating outflows exceeding financing inflows.

Outlook, Risks, and Management Commentary

• Liquidity: Management believes existing cash resources ($120.4 million) are sufficient to fund operations for at least the next 12 months. However, the company expects to incur significant losses for the foreseeable future and will require additional capital to advance clinical trials and commercialization.
• CVR Liability: The company holds a significant liability of $405.9 million related to Contingent Value Rights (CVRs). This liability is settled solely through future cash flows from the Sobi License agreement (milestones and royalties). The increase in the liability's fair value during the quarter was primarily due to the passage of time.
• Key Risks: Risks include the uncertainty of clinical trial outcomes, the ability to secure future funding on favorable terms, and the potential for the CVR liability to increase further. The company also faces risks related to its dependence on third-party manufacturers and contract research organizations.
• Guidance: No specific financial guidance was provided. The company reiterated its focus on advancing Descartes-08 for MG and myositis.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the 12-month liquidity estimate given the high burn rate and potential for increased clinical costs.
• CVR Liability Volatility: Monitor the quarterly fair value adjustments of the $405.9 million CVR liability, as these non-cash charges significantly impact reported net loss.
• ATM Offering Capacity: Confirm the remaining capacity under the $100 million "at-the-market" sales agreement and the pace of future equity dilution.
• Clinical Milestones: Track progress of the Phase 3 AURORA trial for Descartes-08, as success is critical for future revenue generation and potential CVR payouts.
• Grant Funding: Assess the sustainability of NINDS grant revenue, which has shown volatility between quarters.